Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Eli Lilly reported this morning ... I don't make TV shows, I make posters. He said, don't come to me with a pitch, come to me with a poster, because what I need is a placard that we can put ...

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced today a poster presentation at SECO 2025 being held from February 26 ? March 2 in Atlanta, Georgia. Mile Brujic, OD, FAAO of Premier ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

A Palestinian man serving 18 life sentences for a pair of bus bombings in 2004 speaks to NPR days after his release. And, the ...

People who get moderate to vigorous physical activity may be less likely to develop dementia, stroke, anxiety, depression, and sleep disorders, according to a preliminary study released February 27, ...

Having the poster child of artificial intelligence ... Novo Nordisk's Wegovy and Eli Lilly's Zepbound have patents protecting their GLP-1 treatments dedicated to weight loss, but an FDA loophole ...

today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314. “This is a significant milestone for our efforts to ...

Poster POS1075. Congreso EULAR 2022. Acknowledgements: The authors thank IQVIA and Carmen Barrull and Marco Pinel for providing medical editorial assistance with this presentation. Disclosure of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.